ライフサイエンスコーパス: leukocyte count

1 cal inflammation (elevated polymorphonuclear leukocyte count).

2 rse outcomes, with the possible exception of leukocyte count.

3 ease is unassociated with a reduction in the leukocyte count.

4 ex, histology, probability of diagnosis, and leukocyte count.

5 rs of fibrinogen, log C-reactive protein, or leukocyte count.

6 ed with low steady-state hemoglobin and high leukocyte count.

7 logy Group 8602, matched on age, gender, and leukocyte count.

8 tment regimen, risk classification, age, and leukocyte count.

9 termined serum LL-37 levels as a function of leukocyte count.

10 , and confounders previously associated with leukocyte count.

11 ith CSF immunoglobulin G (IgG) synthesis and leukocyte count.

12 scular endothelial growth factor (VEGF), and leukocyte count.

13 ated with sex, age, immunocompromise, or CSF leukocyte count.

14 natriuretic peptide, C-reactive protein, and leukocyte count.

15 ase of the G-CSF successfully normalized his leukocyte count.

16 The high-iron diet alone increased leukocyte count.

17 influenced by fever, not hematocrit, age or leukocyte counts.

18 was quantified 6 hours later by pouch fluid leukocyte counts.

19 Vehicle challenge did not increase leukocyte counts.

20 ictive accuracy compared with the peripheral leukocyte counts.

21 20% Jak2VF CH mice while having no effect on leukocyte counts.

22 al and genetically determined types of blood leukocyte counts.

23 , an adverse event associated with increased leukocyte counts.

24 ociated with loss of organ function and high leukocyte counts.

25 ences observed between the mean differential leukocyte counts.

26 gnificantly more prognostic information than leukocyte counting.

27 83] x 10(9) cells/L, p = 2.32 x 10(-60)) and leukocyte count (0.218 [0.198, 0.239] x 10(9) cells/L, p

28 erican participants had slightly higher mean leukocyte counts (0.16 x 10(9) cells/L; P = 0.014), high

29 (4.2 +/- 0.3 log(10) DNA copies/ml) and high leukocyte counts (143 +/- 62 cells/microl); and patients

30 f 4.8 +/- 0.2 log(10) DNA copies/ml) and low leukocyte counts (22 +/- 7 cells/microl); encephalitis w

31 ng categories of immune cells were elevated: leukocyte count (31 studies, standardized mean differenc

32 8.8 [6.5] years; 54 boys [62.8%]; mean [SD] leukocyte count, 52 600 [74 000] cells/uL) and 359 White

33 9.1 [6.2] years; 189 boys [52.6%]; mean [SD] leukocyte count, 54 500 [91 800] cells/uL); 70 individua

34 ts (P < 0.001), and a higher median absolute leukocyte count (7.2 vs. 4.2 x 103/mm3, P < 0.001).

35 (6.50-7.49 x 10(3)/mm(3)) and highest normal leukocyte counts (7.50-9.99 x 10(3)/mm(3)) were correlat

36 -11 cells x 10(9)/L]), a normal differential leukocyte count (74% neutrophils [normal range, 40%-80%]

37 -11 cells x 10(9)/L]), a normal differential leukocyte count (74% neutrophils [normal range, 40%-80%]

38 3.0 +/- 0.2 log(10) DNA copies/ml) with high leukocyte counts (88 +/- 57 cells/microl).

39 This resulted in a 10-fold increase in leukocyte count, a 3-fold increase in platelets, and mob

40 ears or older (P = .005), those with initial leukocyte count above 50 x 10(9)/L (P = .03), and those

41 Leukocytosis refers to an increase in leukocyte count above the normal range in the blood and

42 haracteristics of the child (age), leukemia (leukocyte count, acquired genetic characteristics) and e

43 In multivariable analysis, a higher leukocyte count (adjusted odds ratios [aOR] 1.10; 95% CI

44 or necrosis factor-alpha, interleukin-6, and leukocyte counts (all p < 0.001).

45 The exudate leukocyte count and adenosine concentration were determi

46 A high leukocyte count and an elevation in inflammatory markers

47 l logistic regression confirmed that initial leukocyte count and antibiotic use were independently as

48 Leukocyte count and CD64 expression on neutrophils (nCD6

49 ogic evidence for a relationship between the leukocyte count and coronary heart disease (CHD).

50 presentations in adults, outperforming both leukocyte count and CRP, thus potentially providing subs

51 y proportional to the baseline QTc level and leukocyte count and directly proportional to the basal h

52 sely proportional to baseline QTc levels and leukocyte count and directly to basal heart rates(p<0.01

53 ue, the author examined the relation between leukocyte count and erythrocyte sedimentation rate and d

54 ggested an inverse association between total leukocyte count and not only aerobic fitness but also pa

55 p between incident PD, baseline differential leukocyte count and other blood markers of acute inflamm

56 e investigated the association between total leukocyte count and physical fitness in a military cohor

57 Different timing of measurements of leukocyte count and serum creatinine level around the CD

58 m, which predicted cerebrospinal fluid (CSF) leukocyte count and survival of Vietnamese patients with

59 o, we assigned 2 points to age and 1 each to leukocyte count and thrombosis.

60 Subsequent laboratory analyses comprised leukocyte counting and differentiation, platelet countin

61 Elevations of the hepatic transaminases and leukocyte counts and a decline in hematocrit count were

62 inflammation was assessed using circulatory leukocyte counts and C-reactive protein (CRP) levels.

63 an-treated animals showed increases in total leukocyte counts and enhanced bacterial clearance from b

64 dynamics of alteration in polymorphonuclear leukocyte counts and expression of CD11b adhesion molecu

65 ations in liver-enzyme levels, reductions in leukocyte counts and hematocrit levels, and a higher inc

66 otypes were also observed, including reduced leukocyte counts and increased presence of autoimmune di

67 d with MRT inflammation, indicated by higher leukocyte counts and inflammatory cytokine concentration

68 Blood was drawn for leukocyte counts and liver function tests.

69 oalveolar lavage fluid, ii) lung parenchymal leukocyte counts and lymphoid aggregates, iii) lung oxid

70 d IL-6, the chemokines MIP-1alpha and MIP-2, leukocyte counts and myeloperoxidase activity (neutrophi

71 studies, we have used PoC biochip to monitor leukocyte counts and nCD64 levels from patients' blood a

72 ressure, lower ultrafiltration rates, higher leukocyte counts and neutrophil-to-lymphocyte ratios.

73 Leukocyte counts and plasma neopterin levels were determ

74 sm had significant increases in platelet and leukocyte counts and reduction in spleen size.

75 Elevations of leukocyte counts and TNF levels in bronchoalveolar fluid

76 ic oxide synthase expression), inflammation (leukocyte count), and angiogenesis (CD31 expression) wer

77 nt age, constitutional symptoms, hemoglobin, leukocyte count, and circulating blasts.

78 raditional and HIV-related CAD risk factors, leukocyte count, and confounders previously associated w

79 e Sequential Organ Failure Assessment score, leukocyte count, and endothelium-dependent vasodilatatio

80 B-precursor leukemia, including age, initial leukocyte count, and hyperdiploidy.

81 After adjusting for age, performance status, leukocyte count, and karyotype in a proportional hazards

82 emonstrated a correlation of CRP, IL-6, PCT, leukocyte count, and LDH with the severity of COVID-19.

83 terized by higher numbers of organ failures, leukocyte count, and mortality compared with ACLF in pat

84 ne C-reactive protein (CRP), fibrinogen, and leukocyte count, and recorded admissions due to ischemic

85 the intranasal route, and bacterial burdens, leukocyte counts, and cytokine levels were determined.

86 duction of inflammatory response by lowering leukocyte counts, and for Lp299 IL-6 levels in rectal mu

87 pot, gut-homing CD8 T cells, intraepithelial leukocyte counts, and HLA-DQ2-restricted gluten-specific

88 We reviewed the histology, leukocyte counts, and PCR data for inflammatory genes, t

89 tically significant reduction in hemoglobin, leukocyte counts, and platelet counts that did not need

90 yed-type hypersensitivity responses, lowered leukocyte counts, and reduced lymphocyte proliferation a

91 lky disease, lower hemoglobin levels, higher leukocyte counts, and similar diffuse uptake in the sple

92 usly elevated levels of CRP, fibrinogen, and leukocyte count are associated with a two- to fourfold i

93 Blood leukocyte counts are easily accessible markers of immune

94 these mice, even at ambient air, peripheral leukocyte counts are elevated by 1.7-fold and neutrophil

95 more specific assay is warranted or in which leukocyte counts are inadequate to perform cell-based as

96 leukopenia, with a mean decline of 12.8% in leukocyte count at 24 mo versus 47.2% in nonsplenectomiz

97 FLT3/ITD-positive patients had higher median leukocyte count at diagnosis (59 v 21 x 10(9)/L; P < .00

98 multivariable analysis, risk group (age and leukocyte count at diagnosis) and asparaginase treatment

99 ostic significance after adjustment for age, leukocyte count at diagnosis, and genetic subtype.

100 mg/m2 > 100 mg/m2; P=0.00001), logarithm of leukocyte count at the time of diagnosis (P=0.0005), and

101 did not differ in gender, immune phenotype, leukocyte count at the time of diagnosis, chromosome abn

102 ther the level of C-reactive protein nor the leukocyte count at the time of PET/MRI was related to th

103 used significant increases from prechallenge leukocyte counts at 10 min (p<0.03), 30 min (p<0.01), an

104 Further adjustment for weight change and leukocyte count attenuated these risks substantially.

105 Both platelet and leukocyte counts became normal in splenic patients, wher

106 Cases had higher latest leukocyte count before CAD event than controls (median [

107 Cerebrospinal fluid leukocyte counts began to decrease by day 13 of treatmen

108 there were no differences in BAL fluid total leukocyte counts between resistant and susceptible subje

109 glycerides, cholesterol, C-reactive protein, leukocyte count, blood pressure, and Framingham risk sco

110 , fibrinogen levels, chronic kidney disease, leukocyte count, C-reactive protein levels, homocysteine

111 is of favorable age and has a low presenting leukocyte count, can be cured with chemotherapy alone.

112 CSF leukocyte counts, CD4(+) and CD8(+) T cells, CD19(+) B c

113 gher platelet count and lower hemoglobin and leukocyte count compared with JAK2- and MPL-mutated pati

114 effects (percentage decrease in circulating leukocyte counts) compared with MP alone (-50% +/- 4%, -

115 n 1 hr of lipopolysaccharide infusion, total leukocyte counts decline.

116 human heart transplant recipients the total leukocyte count decreased prior to the time of diagnosis

117 e measurements presented significantly lower leukocyte counts determined by the MIC.

118 C-reactive protein, leukocyte count, duration of antibiotic treatment, and t

119 ts displayed significantly higher peripheral leukocyte counts, early depletion of common lymphoid pro

120 Multivariate analysis confirmed leukocyte count, Eastern Cooperative Oncology Group perf

121 Treatment with 901 induced a durable drop in leukocyte counts, enhanced erythropoietic function, and

122 mples originating from donors with differing leukocyte counts exhibited dramatic differences in both

123 sma cytokines levels, total and differential leukocyte counts, expression of leukocyte cell surface r

124 ty C-reactive protein, ankle-brachial index, leukocyte count, fasting blood glucose, periodontal dise

125 y, lipoprotein(a) level, homocysteine level, leukocyte count, fasting blood glucose, periodontal dise

126 n decision curve analysis than either CRP or leukocyte count for discriminating viral infections from

127 The median baseline leukocyte count for patients with leukocytosis was 3,900

128 No significant differences in age, sex, leukocyte count, French-American-British subtype, or kar

129 reported fever (OR, 8.3 [CI, 1.6 to 50.0]), leukocyte count greater than 10 x 10(9)/L (OR, 4.0 [CI,

130 ome (P <.001), and no patient without a peak leukocyte count greater than 10,000 cells/microL develop

131 sk prognostic features, including an initial leukocyte count greater than 100 x 10(3)/ microL, a T-ce

132 e prophylaxis and exclusion of patients with leukocyte counts greater than 200x10(9)/L have made this

133 its; hematopoietic, platelet count > 50 K or leukocyte count > 4.5 K, mortality, and costs.

134 (CRP > 3 mg/L, fibrinogen > 14 mumol/L, and leukocyte count > 9 x 10(9)/L) versus individuals with a

135 temperature > or = 100.5 and a preoperative leukocyte count > or = 10,000 were incapable of discrimi

136 onclusion, IPSET, based on age >/= 60 years, leukocyte count >/= 11 x 10(9)/L, and history of thrombo

137 Age 60 years or older, leukocyte count >/= 11 x 10(9)/L, and prior thrombosis s

138 , immunocompromise (1.07 [.57-2.03]), or CSF leukocyte count >1000 x 10 x 6/L (0.78 [.33-1.84]).

139 ciated with age less than 1 year (P < .001), leukocyte count >50 x 10(9)/L (P = .003), and the absenc

140 .15 [1.04-1.27] per mmol/L decrease), higher leukocyte count >=13.0 x 103/muL (2.35 [1.17-4.72]) and

141 luded younger age (0.77 [.69-.85] per year), leukocyte count >=13.0 x 103/muL (2.54 [1.42-4.54]), hig

142 r modality should be retained for cases with leukocyte counts > 100 x 10(9)/L.

143 ation >12 mmol/L, Na(+) : K(+) >1, and total leukocyte counts > or =10(6) cells/mL, respectively.

144 .6), to cough >/=14 days (aOR, 6.3), to have leukocyte counts >20 000 cells/microL (aOR, 4.6), and to

145 male sex, the absence of surgical resection, leukocyte counts >6.0 x 10(9)/L, and levels of hemoglobi

146 body temperature>38 or <36 degrees C, or 4) leukocyte count>12 or<4x10/L.

147 ollowed by measuring body weight, peripheral leukocyte counts, GVHD, survival, and cytokine response.

148 Higher leukocyte count has been associated with coronary artery

149 PWH in Switzerland with higher leukocyte counts have an independently increased risk of

150 0%, platelet count lower than 150 x 10(9)/L, leukocyte count higher than 25 x 10(9)/L before transpla

151 or event-free survival identified older age, leukocyte count higher than 30 x 10(9)/L, presence of Ph

152 association between house dust endotoxin and leukocyte count in a national survey.

153 MTX significantly reduced the exudate leukocyte count in C57BL/6J and BALB/cJ mice, but not DB

154 Apart from a significantly higher leukocyte count in E. histolytica-positive patients than

155 ly elevated levels of CRP and fibrinogen and leukocyte count in individuals with COPD were associated

156 the effect of IL-1 blockade with anakinra on leukocyte count in patients with STEMI is unknown.

157 ith ~80% collection efficiency, reducing the leukocyte count in recirculating blood by nearly half af

158 te counts were observed, except for a higher leukocyte count in the dexamethasone group at Day 3.

159 mice with i.p. bilirubin decreases the total leukocyte count in the lung parenchyma and lavage fluid,

160 DE and PDDE each increased total peripheral leukocyte counts in a manner affected by participant gen

161 CSF examination at 3 months showed decreased leukocyte counts in all patients; however, 23.3% still h

162 Although no differences in total leukocyte counts in chamber fluids were observed between

163 dust endotoxin concentration and peripheral leukocyte counts in human subjects.

164 Differential leukocyte counts in the normal clinical range from finge

165 GF-beta1 were thus correlated with the total leukocyte counts in the synovial fluids.

166 Polymorphonuclear leukocyte counts increased through the following 3- and

167 The peripheral leukocyte count is a biomarker of inflammation and is as

168 The leukocyte count is a marker of inflammation that is wide

169 The leukocyte count is inexpensive, reliable, easy to interp

170 y with CSF markers of neuroinflammation (ie, leukocyte count, lactate concentration, and blood-CSF-ba

171 cating a favorable prognosis were presenting leukocyte count less than 50 x 10(9)/L (relative risk of

172 both AL patients (P = .01) and patients with leukocyte counts less than 100/mm(3) (P = .001).

173 igh-risk features, including older age, high leukocyte count, leukemia with a T-cell phenotype, the P

174 analysis, adjusting for sex, age, presenting leukocyte count, leukemic cell DNA index, immunophenotyp

175 mice also had significantly lower pulmonary leukocyte counts, lower interleukin 1beta and interferon

176 mes were the occurrence of hematologic ADRs (leukocyte count < 3.0*10(9)/L or reduced platelet count

177 ex, middle age (age, 30-60 years), headache, leukocyte count <10 x 10(9)/L and C-reactive protein lev

178 temperature >38 degrees C or <=36 degrees C; leukocyte count <4000/muL or >10 000/muL) or symptoms (e

179 /FiO(2) <= 200 mm Hg (P = .026), and pre-LT leukocyte count <=10 G/L (P = .004).

180 Despite a similar total leukocyte count, Ly6C(high) monocytes displayed reduced

181 esulted in normalization of peripheral blood leukocyte counts, marked reduction of spleen size, and a

182 Peripheral leukocyte count may be influenced by residential endotox

183 e participants, black participants had lower leukocyte counts (mean difference, 0.89 x 10(9) cells/L;

184 (75%), in their seventh decade, and with low leukocyte count (median, 2 x 109/L), low bone marrow bla

185 or use of erythropoiesis-stimulating agents, leukocyte count more than 11 x 10(9)/L, and body mass in

186 L patients (P = .0003), and in patients with leukocyte counts more than 100/mm(3) (P = .002).

187 dence interval, 1.33-36.5) for patients with leukocyte counts more than 100/mm(3).

188 mite-treated Adam8(-/-) mice had higher lung leukocyte counts, more airway mucus metaplasia, greater

189 Polymorphonuclear leukocyte counts, murine GRO-alpha (KC), and macrophage

190 Total leukocyte counts, myeloperoxidase, nitric oxide producti

191 applied using genetic instruments for blood leukocyte counts (n = 563 085); for AD, the European Alz

192 Blood glucose level, total leukocyte count, neutrophil count, and leukocyte labelin

193 Additional biomarkers, including leukocyte count, neutrophils, ferritin, interleukin (IL)

194 clinical factors, such as age and presenting leukocyte count, no longer identify the 20% of newly dia

195 Differential leukocyte counts obtained from fingerprick samples accur

196 proportional hazards for participants with a leukocyte count of > or = 9.1 x 10(9)/liter compared wit

197 0(9)/liter compared with participants with a leukocyte count of < or = 5.7 x 10(9)/liter were 1.33 (9

198 patients who had T-cell ALL and a presenting leukocyte count of 100 x 10(9)/L or more, or CNS-3 (5 or

199 10 g/dL; normal range, 12-15 g/dL), a total leukocyte count of 14 000 cells per microliter (14 cells

200 ved in all patients; leukopenia (with median leukocyte count of 1400/mm3) was the most commonly effec

201 ase 125 ng/mL or higher (1.81, 1.20-2.75), a leukocyte count of 16 x 10(9) per L or higher (1.88, 1.2

202 The leukocyte count of 213,000/cu mm, being among the highes

203 normal range, 140-440 x 10(3)/uL), and total leukocyte count of 7100 cells/uL (normal range, 4500-11

204 (normal range, 140-440 x 103/uL), and total leukocyte count of 7100 cells/uL (normal range, 4500-11

205 .1 g/dL (reference range, 13.8-17.5 g/dL), a leukocyte count of 8.1 x 10(9)/L (reference range, [3.4-

206 2.4 g/dL; normal range, 12-15 g/dL), a total leukocyte count of 9000 cells per microliter (9 cells x

207 The patients had to have a leukocyte count of at least 3000 per cubic millimeter, a

208 Neither the leukocyte counts on day 0 nor those during the 6-day neu

209 w cytometry to assess the influence of donor leukocyte counts on the transcriptional composition of w

210 use (AOR, 2.78; 95% CI, 1.04-7.48), and high leukocyte counts on vaginal smear (AOR, 1.18; 95% CI, 1.

211 lly significant reduction in erythrocyte and leukocyte counts; only the reduction in erythrocyte coun

212 There were no perturbations of the leukocyte count or differential noted.

213 ration, and Kyn/Trp concentration ratio with leukocyte count or lactate concentration were accurate c

214 ere assessed 2 days later for VEGF ELISA and leukocyte counting or 1 week later for quantification of

215 otein (OR = 1.16; 95% CI = 1.02-1.31), blood leukocyte count (OR = 1.39;95% CI = 1.09-1.77), serum al

216 on, ICU admission was predicted by increased leukocyte count (P < .0001), alanine aminotransferase (P

217 , while mortality was predicted by increased leukocyte count (P = .0005) and elevated LDH (P < .0001)

218 AL overexpression was associated with a high leukocyte count (P = 0.007) and was independently associ

219 kin-6 concentration (p < 0.001) and alveolar leukocyte count (p = 0.03) and a minor increase in bronc

220 ses in symptoms, temperature (P=.016), total leukocyte count (P=.014), tumor necrosis factor-alpha (P

221 tion: (a) younger age (P < 0.008); (b) lower leukocyte count (P=0.01); (c) the presence of Auer rods

222 nths for platelet counts, hemoglobin levels, leukocyte counts (P < .001), and ET-related events (HR,

223 ors had higher D-dimer levels (P = .008) and leukocyte counts (P < .001), and lower hemoglobin levels

224 associations between periodontitis and total leukocytes counts (p < 0.001), neutrophil counts (P <0.0

225 edimentation rate (ESR), C-reactive protein, leukocyte count, presence of antinuclear antibodies (ANA

226 us humor of the right eyes was collected for leukocyte count, protein concentration, and IL-6 assay.

227 This was confirmed by decreases in leukocyte count, protein concentration, and IL-6 level i

228 The LL-37/leukocyte count ratio correlates highly significantly in

229 Our results indicate that the LL-37/leukocyte count ratio could be used to assess the risk o

230 1.38 (1.19 to 1.59) for waist circumference, leukocyte count, serum albumin, and fibrinogen, respecti

231 Adjusting for age, leukocyte count, sex, era of treatment, and leukemia bla

232 tors such as age at diagnosis and presenting leukocyte count should be taken into consideration when

233 of endpoints (i.e., transcriptomic analysis, leukocyte counts, spleen index, hematocrit, bacterial lo

234 Balb/c mice demonstrating markedly elevated leukocyte counts, splenomegaly, and reticulin fibrosis c

235 stratified for age (subdivided at 10 years), leukocyte count (subdivided at 50,000), and gender, the

236 Third, the reduction in leukocyte count that occurs during CMV disease appears t

237 tive biomarkers include elevated platelet or leukocyte counts, tissue factor, soluble P-selectin, and

238 , 95% CI 1.12-1.18) adjusting for age, Total Leukocyte count (TLC) and pretreatment levels of ALT, ir

239 conjugates, or failure of the total absolute leukocyte count to accurately reflect the population use

240 Hemodynamic parameters, leukocyte counts, total left ventricular weight, and are

241 ate the utility to prioritize variants using leukocyte count trait and analyze variants in linkage di

242 rotein (CRP) was 0.833 (0.694-0.944) and for leukocyte count was 0.938 (0.840-0.986).

243 6 mg/dL (IQR, 1.2-7.5 mg/dL), and the median leukocyte count was 10.0 x 103/uL (IQR, 8.2-12.2 x 103/u

244 rs, and the median cerebrospinal fluid (CSF) leukocyte count was 360 (166-670) x 10 x 6/L, with a mon

245 On the contrary, having no response in leukocyte count was associated with higher risk of death

246 response to RA treatment, an increase in the leukocyte count was noted.

247 complete blood count, including differential leukocyte counts, was performed on blood samples collect

248 Levels of CRP and fibrinogen and leukocyte count were defined as high or low according to

249 calcitonin, C-reactive protein, lactate, and leukocyte count were determined at admission and 12-24 h

250 C-reactive protein (CRP) and fibrinogen and leukocyte count were measured in participants at a time

251 Proinflammatory cytokines and increased leukocyte counts were also found in the eyes of infected

252 Higher CLIF-SOFA scores and leukocyte counts were independent predictors of mortalit

253 rly, no differences in C-reactive protein or leukocyte counts were observed, except for a higher leuk

254 On-treatment leukocyte counts were obtained every 2-6 weeks.

255 Total and differential leukocyte counts were performed on blood samples collect

256 Leukocyte counts were recorded during the first 4 days f

257 Monocyte and leukocyte counts were reduced, and the activation state

258 Baseline and peak leukocyte counts were similar between Mac-1(-/-) and WT,

259 Therefore, the patterns of changes in leukocyte counts were similar, with little evidence that

260 kers (C-reactive protein, procalcitonin, and leukocyte count) were not significantly different pre-ad

261 sodium : potassium ratio [Na(+) : K(+)], and leukocyte count) were related to breast milk HIV-1 RNA a

262 in haematopoietic ANGPTL4 have higher blood leukocyte counts, which is associated with an increase i

263 infected catheters, suggesting that coupling leukocyte counts with inflammatory mediators may differe

264 For leukocyte count, with 5337 CHD cases in the 7 largest st

265 n treatment also alters circadian rhythms of leukocyte counts within the lung in a bmal1-dependent ma

266 ccording to equally sized quartiles of total leukocyte counts within the suggested normal limits (4.0

267 sis access, hemoglobin, serum albumin, blood leukocyte count, Wright/Khan index, and eC(Cr) at the st